Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 October 2024
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 April 2024
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 January 2023
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 October 2022
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) (TA785)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 April 2022
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 March 2022
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 September 2020
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 September 2020
Cabozantinib for untreated advanced renal cell carcinoma (TA542)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 October 2018
Tivozanib for treating advanced renal cell carcinoma (TA512)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 March 2018
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2018
Immunosuppressive therapy for kidney transplant in adults (TA481)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 August 2017
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2017
Nivolumab for previously treated advanced renal cell carcinoma (TA417)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 November 2016
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 August 2013Published: 23 February 2011
Irreversible electroporation for treating renal cancer (IPG443)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 February 2013
Single-port laparoscopic nephrectomy (IPG414)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 November 2011
Laparoscopic cryotherapy for renal cancer (IPG405)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 August 2011
Percutaneous cryotherapy for renal cancer (IPG402)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 July 2011
Percutaneous radiofrequency ablation for renal cancer (IPG353)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 July 2010
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 August 2009
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2009
Laparoscopic partial nephrectomy (IPG151)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 January 2006
Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 August 2005
Laparoscopic live donor simple nephrectomy (IPG57)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 May 2004
Improving outcomes in urological cancers (CSG2)Product type:GuidanceProgramme:Cancer service guidelinePublished: 19 September 2002
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)Product type:AdviceProgramme:Medtech innovation briefingPublished: 4 October 2022
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Renal cell carcinoma Pathways Pilot [ID6186]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Signatera molecular residual disease assay (MT741)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor ID 6476Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC